Eversept Partners LP Sells 450,142 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Eversept Partners LP lessened its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 22.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,600,015 shares of the company's stock after selling 450,142 shares during the quarter. Vera Therapeutics accounts for about 6.0% of Eversept Partners LP's investment portfolio, making the stock its 3rd largest holding. Eversept Partners LP owned approximately 2.53% of Vera Therapeutics worth $67,665,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Huntington National Bank purchased a new stake in shares of Vera Therapeutics in the fourth quarter worth about $26,000. AlphaQuest LLC purchased a new position in Vera Therapeutics in the 4th quarter worth approximately $34,000. KBC Group NV grew its position in Vera Therapeutics by 127.2% in the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after acquiring an additional 1,387 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in shares of Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after purchasing an additional 639 shares during the period. Finally, Moors & Cabot Inc. acquired a new position in shares of Vera Therapeutics during the fourth quarter worth $220,000. Hedge funds and other institutional investors own 99.21% of the company's stock.

Vera Therapeutics Stock Down 1.1 %

NASDAQ VERA traded down $0.25 on Friday, hitting $23.22. 906,424 shares of the stock traded hands, compared to its average volume of 748,418. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average of $25.27 and a 200 day moving average of $35.86. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61. The company has a market capitalization of $1.48 billion, a P/E ratio of -8.90 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.11. As a group, analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on VERA shares. JPMorgan Chase & Co. lowered their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. Guggenheim raised their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price target on the stock. Finally, Wolfe Research initiated coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price objective for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $64.67.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.